A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Official Title

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)


This is a multicentre, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumour activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).

Trial Description

Primary Outcome:

  • Incidence of dose-limiting toxicities (DLTs) (Part 1)
  • Incidence of adverse events (Part 1)
  • Incidence of lab abnormalities (Part 1)
  • Objective response rate (ORR) (Part 2)
Secondary Outcome:
  • Objective response rate (ORR) (Part 1)
  • Disease control rate (Parts 1 and 2)
  • Duration of response (Parts 1 and 2)
  • Clinical benefit rate (Parts 1 and 2)
  • Progression-free survival (Parts 1 and 2)
  • Overall survival (Parts 1 and 2)
  • Incidence of anti-drug antibodies (ADAs) (Parts 1 and 2)
  • End of infusion concentration of ZW25 (Parts 1 and 2)
  • Maximum serum concentration of ZW25 (Parts 1 and 2)
  • Trough concentration of ZW25 (Parts 1 and 2)
  • Incidence of adverse events (Part 2)
  • Incidence of lab abnormalities (Part 2)
Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the recommended dosage (RD) of ZW25 when administered in combination with each of these multi-agent chemotherapy regimens. Then, Part 2 of the study will evaluate the anti-tumour activity of ZW25 plus combination chemotherapy in HER2-expressing GEA, BTC, and CRC.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society